CALYPTE - noch mehr News! CALY to present at the Wall Street Analyst Forum!!! - 500 Beiträge pro Seite

[Wallgrekk]

(BSNS WIRE) Calypte Biomedical to Present at the Wall Street Analyst Forum
Calypte Biomedical to Present at the Wall Street Analyst Forum 47Th Annual
Institutional Investor Conference


Business Editors

ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 5, 2003--Calypte Biomedical
Corporation (OTCBB:CALY), the developer and marketer of the only two
FDA approved HIV-1 antibody tests that can be used on urine samples,
as well as an FDA approved serum HIV-1 antibody Western blot
supplemental test, today announced that it will be presenting at the
Wall Street Analyst Forum 47th Institutional Investor Conference at
The Roosevelt Hotel in New York City, New York on Monday, February 10,
2003 at 9:00 a.m. ET.
Presenting for Calypte will be Tony Cataldo, chairman and Nancy
Katz, president and CEO. The webcast presentation will also be
broadcast over the Internet. To listen to the presentation, please go
to the investor`s section of Calypte`s web site at www.calypte.com and
register for the webcast presentation. An archived replay will be
available after the conclusion of the presentation for 30 days.

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda,
California, is a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products
and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually
transmitted diseases and other infectious diseases. Calypte`s tests
include the screening EIA and supplemental Western Blot tests, the
only two FDA-approved HIV-1 antibody tests that can be used on urine
samples. The company believes that accurate, non-invasive urine-based
testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an
environment in which testing may be done safely, economically, and
painlessly. Calypte markets its products in countries worldwide
through international distributors and strategic partners. Current
product labeling including specific product performance claims can be
found on our website at www.calypte.com.

--30--LR/sf*

CONTACT: Calypte Biomedical Corporation
Nancy Katz, 510/749-5100
[e-mail]
or
Lippert/Heilshorn & Associates
Brendan Lahiff/Kirsten Chapman, 415/433-3777 (IR)
[e-mail]

KEYWORD: NEW YORK CALIFORNIA
INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY ADVISORY MEDICAL
SOURCE: Calypte Biomedical Corporation

Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com

[jojobada]

da geht aber richtig was ab
sollten Ctaldo und co sich doch bemühen ??

Geschäft Herausgeber ALAMEDA, Calif. -- (BUSINESS WIRE) -- Feb. 5, 2003 -- Calypte Biomedical Corporation (OTCBB:CALY), der Entwickler und der Marketingspezialist der einzigen FDA zwei genehmigte Tests des Antikörpers Hiv-1, die auf Urinproben benutzt werden können, sowie ein FDA genehmigter zusätzlicher Test des westlichen Flecks des Antikörpers des Serums Hiv-1, verkündete heute, daß er sich bei der Anleger-Konferenz des Wall Street Analytiker-Forum-47th im Roosevelt Hotel in New York City darstellen wird, neues York am Montag, Februar 10, 2003 um 9:00 a.m.. UND. Das Darstellen für Calypte ist Tony Cataldo, Vorsitzender und Nancy Katz, Präsident und CEO. Die webcast Darstellung ist auch Sendung über dem Internet. Um zur Darstellung zu hören, gehen Sie bitte zum investor`s Abschnitt von Calypte`s Web site an www.calypte.com und registrieren Sie für die webcast Darstellung. Archiviert replay ist vorhanden nach der Zusammenfassung der Darstellung für 30 Tage.

[steffen712000]

was die so alles präsentieren

präsentieren und wieder präsentieren! investoren werden sie immer zu 2 cent finden. nur das diese investoren ihre stücken zu mehreren 100% weider af den markt schmeissen, haben hier nur die wenigsten, also die beobachter, gerafft!

kauft nur weiter!!!


PS: sollten nicht langsam umsatzwirksame news kommen, um ein wenig RICHTIGE phantasie aufkommen zu lassen???

[Wallgrekk]

Capital Research Group Announces Investment Opinion: Stock WatchList!

WESTON, FL, Feb. 05, 2003 (INTERNET WIRE via COMTEX) -- Keep an eye on Elgrande.com Inc. (OTC BB: EGND). EGND has just released major news that the Company`s excellent performance has led to an Exclusive North America wide Representation Agreement with a major manufacturer! Other stock market standouts include: International BioChemical Industries (OTC BB: IBCL): Market Underperform, down 20% on 19 million shares, Rambus Inc. (NASDAQ: RMBS): Market Underperform, down 4% on 14 million shares, Calypte Biomedical Corp. (OTC BB: CALY): Market Outperform, down 19% on 9 million shares.

"Much unlike the previous session, stocks never saw the light of day on Tuesday, with both major averages starting well below the flat line, and staying there through to the close. The telecom sector in particular caught the brunt of the selling in afternoon dealings, after the release of some less than encouraging outlooks from key players in the group, namely Alcatel and Ericsson," stated Peter Antipatis. More is available at: www.thesubway.com/sub_comm.asp.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (one million shares for EGND) CRG intends to sell its shares. CRG has sold approximately zero EGND shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Peter Antipatis, CRD number 2955420. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.



CONTACT: Charles T. Tamburello
Capital Research Group Inc.
954-217-9555



Copyright 2003 Internet Wire, All rights reserved.

-0-



SUBJECT CODE: Business/Finance:Small Business:Investment Opinion
Business/Finance: General:Investment Opinion

[Wallgrekk]

Geht wirklich gut ab das Teil!!

+17.3% heute!!